MASHINIi

Cytokinetics, Incorporated.

CYTK.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products

Cytokinetics, Incorporated is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-generation muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. The compan...Show More

Ethical Profile

Mixed.

Cytokinetics faces an ongoing securities fraud investigation by the Schall Law Firm and DJS Law Group, alleging potential misleading of investors regarding its aficamten drug, which followed an FDA delay and a 12% stock drop. As a biopharmaceutical company, its core business necessitates animal testing for preclinical drug development, though it states adherence to U.S. National Institutes of Health standards and the 3Rs principles. Cytokinetics' primary mission is to develop treatments for debilitating diseases like heart failure. In environmental efforts, the company reduced natural gas consumption by 43% in 2024, partnered to recycle 65 kg of lab waste in two months, and aims for a 75% reduction in landfill waste.

Value Scores

Better Health for All0
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect20
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals-40
-100100
No War, No Weapons0
-100100
Planet-Friendly Business0
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products-50
-100100

Better Health for All

0

No evidence available to assess Cytokinetics, Incorporated on Better Health for All.

Fair Money & Economic Opportunity

0

Cytokinetics is a biopharmaceutical company and does not offer lending, deposit, or other traditional financial services to consumers.

1
Therefore, KPIs related to financial products, APRs, fees, loan books, debt ratios, and open banking APIs are not applicable. The company's MYQORZO & You programs offer financial assistance for medication, including a Copay Savings Program allowing eligible patients to pay as little as $5 per month and a Patient Assistance Program providing MYQORZO at no cost to eligible patients.
2
These programs do not charge membership fees.
3
The company aims to ensure equitable access and affordability of its medicines and helps patients understand their insurance coverage.
4
It also provides disease and product education.
5

Fair Pay & Worker Respect

20

In 2024, the CEO to median employee pay ratio was 35:1.

1
The company offers a variety of comprehensive health benefits, including medical, dental, vision, life, and disability insurance, alongside financial benefits such as a 401(k) plan and an employee stock purchase plan.
2
Employees receive 20 days of paid time off annually, paid holidays, a winter shutdown, 8 weeks of paid new parental/baby bonding leave, and up to 12 weeks of paid medical leave.
3
The company promotes a diverse and inclusive workplace and aims to increase diverse representation for women and underrepresented groups in leadership.
4

Fair Trade & Ethical Sourcing

0

No evidence available to assess Cytokinetics, Incorporated on Fair Trade & Ethical Sourcing.

Honest & Fair Business

0

Cytokinetics, Incorporated is currently under investigation by Schall Law Firm and DJS Law Group for potential securities fraud violations.

1
The investigation alleges possible misleading of investors regarding potential delays in the regulatory path for its drug candidate, aficamten.
2
This follows the FDA's extension of the PDUFA action date for aficamten to December 26, 2025, to allow for a full review of the Risk Evaluation and Mitigation Strategy (REMS).
3
News of this FDA delay led to a nearly 15% drop in CYTK stock on May 2, 2025.
4

Kind to Animals

-40

Cytokinetics is licensed by the State of California Department of Public Health to keep and use laboratory animals.

1
The company states that its animal care adheres to the standards set by the U.S. National Institutes of Health’s Guide for the Care and Use of Laboratory Animals and follows the principles of Reduction, Refinement, and Replacement (the 3Rs).
2
However, the provided articles do not offer specific details on measurable goals, enforcement mechanisms, or reporting related to these principles, indicating a commitment in principle without disclosed accountability.

No War, No Weapons

0

No evidence available to assess Cytokinetics, Incorporated on No War, No Weapons.

Planet-Friendly Business

0

No evidence available to assess Cytokinetics, Incorporated on Planet-Friendly Business.

Respect for Cultures & Communities

0

No specific, quantitative data points were found across the provided articles for any of the KPIs related to 'Respect for Cultures & Communities'.

1
While articles mention general corporate contributions and community engagement, they do not provide the precise metrics required by the rubric, such as the percentage of revenue reinvested in local community development, the number of formal partnerships with indigenous groups, or details on cultural impact assessments or cultural preservation investments.
2
Therefore, no KPIs can be scored based on the available evidence.

Safe & Smart Tech

0

The company's privacy policy grants users comprehensive control over their personal data, allowing them to access, correct, update, suppress, restrict, or delete their data, withdraw consent, object to or opt out of processing, and request data transfer.

1
The policy states that data is retained only as necessary for business purposes and to comply with laws.
2
Furthermore, the company explicitly mentions its compliance with GDPR, CCPA, and other relevant regulations.
3

Zero Waste & Sustainable Products

-50

In 2022, the company recycled an estimated 72.2 tons of non-hazardous waste and landfilled 200.8 tons, resulting in a waste diversion rate of 26.45%.

1
The company implemented several waste reduction initiatives, including a company-wide program in 2024 that led to a 3% reduction in overall waste and a partnership to recycle lab waste, diverting 65 kg in two months.
2
In 2023, a waste reduction project was initiated with a goal to reduce landfill waste by up to 75% over the next few years.
3
Hazardous waste is stored, handled, and disposed of in compliance with laws and company practices.
4
There were no waste disposal violations reported in the past three years. A Supplier Code of Conduct, which includes waste reduction and recyclability requirements, was drafted and is scheduled to be piloted in 2025.
5

Own Cytokinetics, Incorporated?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.